Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast...
18 KB (1,504 words) - 01:24, 12 October 2024
Quinazoline (section Lapatinib)
drug lapatinib was approved by the U.S. FDA to treat advanced-stage or metastatic breast cancer in combination with Roche's capecitabine. Lapatinib eliminates...
14 KB (1,245 words) - 15:37, 25 October 2024
8 months (30.9 months vs. 25.1 months) compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. Food and Drug Administration...
29 KB (2,696 words) - 14:16, 27 July 2024
vulnerability to oxytosis/ferroptosis via a combination of siramesine and lapatinib. These cells also exhibited an autophagic cycle independent of ferroptotic...
24 KB (2,638 words) - 00:26, 29 August 2024
while attempting to determine the toxicity and effectiveness of the drug. Lapatinib, FDA-approved for treatment in conjunction with chemotherapy or hormone...
10 KB (1,179 words) - 18:31, 8 August 2024
Lantidra Lantrisul Lantus (Sanofi-Aventis) lapaquistat acetate (USAN) lapatinib ditosylate (USAN) lapirium chloride (INN) laprafylline (INN) lapuleucel-T...
4 KB (281 words) - 04:55, 21 August 2024
this setting. Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib...
20 KB (2,234 words) - 01:21, 22 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
68 KB (5,999 words) - 00:04, 25 October 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
10 KB (600 words) - 04:23, 25 October 2024
antibody margetuximab can also prolong survival, as can HER2 inhibitors lapatinib, neratinib, or tucatinib. Certain therapies are targeted at those whose...
136 KB (15,340 words) - 15:27, 28 October 2024
to develop new therapeutic strategies. HER2 kinase inhibitors, such as lapatinib, have also demonstrated clinical efficacy in HER2 overexpressing breast...
18 KB (2,105 words) - 01:40, 20 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
64 KB (7,432 words) - 08:21, 28 October 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
10 KB (1,131 words) - 19:14, 31 March 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
149 KB (15,703 words) - 20:22, 18 October 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
24 KB (1,710 words) - 19:18, 30 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
92 KB (8,729 words) - 03:44, 26 October 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
18 KB (1,573 words) - 05:19, 15 October 2024
Clinical trials are in progress for other drugs such as everolimus, lapatinib and mifepristone. Common aspirin has been studied as a low-risk therapeutic...
59 KB (6,712 words) - 03:57, 19 October 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
42 KB (3,935 words) - 20:28, 27 October 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
15 KB (844 words) - 18:08, 21 March 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
31 KB (3,428 words) - 18:05, 24 October 2024
approved anti-HER2 therapeutics are also tyrosine kinase inhibitors (Lapatinib, Neratinib, and Tucatinib) and antibody-drug conjugates (ado-trastuzumab...
43 KB (4,651 words) - 13:41, 27 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
34 KB (3,021 words) - 12:39, 5 August 2024
trastuzumab-containing combination therapies (with chemotherapy, hormone blockers, or lapatinib) for the treatment of metastatic breast cancer.[clarification needed]...
69 KB (6,102 words) - 23:51, 21 October 2024
Huang, Zhen-cong; Chen, Yi-fan; Wang, Xiao-kun; Fu, Li-wu (2014-09-08). "Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug...
66 KB (8,077 words) - 01:32, 24 October 2024
with second-generation inhibitors combined with afatinib, erlotinib and lapatinib. In all cases, the responses were enhanced by the combination with respect...
17 KB (1,951 words) - 10:39, 25 January 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
121 KB (13,799 words) - 18:53, 22 October 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
13 KB (1,177 words) - 02:19, 4 September 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
26 KB (2,420 words) - 02:40, 26 September 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
21 KB (2,162 words) - 15:09, 19 August 2024